382
Views
30
CrossRef citations to date
0
Altmetric
Review Article

Contribution of insulin resistance to vascular dysfunction

, , &
Pages 199-217 | Received 19 May 2009, Accepted 23 Jun 2009, Published online: 17 Aug 2009

References

  • Abe H, Yamada N, Kamata K, Kuwaki T, Shamida M Osuga J, Shionoiri F, Yahagi N, Kadowaki T, Tamemoto H, et al. (1998). Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 101:1784–8.
  • Absher PM, Schneider DJ, Baldor LC, Russell JC, Sobel BE. (1999). The retardation of vasculopathy induced by attenuation of insulin resistance in the corpulent JCR:LA-cp rat is reflected by decreased vascular smooth muscle cell proliferation in vivo. Atherosclerosis 143:245–51.
  • Adhikari N, Charles N, Lehmann U, Hall JL. (2006). Transcription factor and kinase-mediated signalling in atherosclerosis and vascular injury. Curr Atheroscler Rep 8:252–60.
  • Alexander WS, Hilton DJ. (2004). The role of suppressors of cytokine signalling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 22:503–29.
  • Aljada A, Saadeh R, Assian E, Ghanim H, Dandona P. (2000). Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells, through stimulation of nitric oxide. J Clin Endocrinol Metab 85:2572–5.
  • Aljada A, Ghanim H, Assian E, Dandona P. (2002). Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. Metabolism 51:487–91.
  • Andreozzi F, Formoso G, Pridente S, Hribal ML, Pandolfi A, Bellacchio E, Di Silvestre S, Trischitta V, Consoli A, Sesti G. (2008). TRIB3 R84 variant is associated with impaired insulin–mediated nitric oxide produnction in human endothelial cells. Arterioscler Thromb Vasc Biol 28:1355–60.
  • Anfossi G, Cavalot F, Massucco P, Mattiello L, Mularoni E, Hahn A, Trovati M. (1993). Insulin influences immunoreactive endothelin release by vascular smooth muscle cells. Metabolism 42:1081–3.
  • Anfossi G, Massucco P, Mattiello L, Balbo A, Russo I, Doronzo G, Rolle L, Ghigo D, Fontana D, Bosia A, et al. (2002). Insulin influences the nitric oxide cyclic nucleotide pathway in cultured human smooth muscle cells from corpus cavernosum by rapidly activating a constitutive nitric oxide synthase. Eur J Endocrinol 147: 689–700.
  • Anfossi G, Russo I, Doronzo G Trovati M. (2007). Relevance of the vascular effects of insulin in the rationale of its therapeutical use. Cardiovasc Hematol Disord Drug Targets 7: 228–49.
  • Arai A, Jin A, Yan W, Mizuchi D, Yamamoto K, Nanki T, Miura O. (2005). SDF-1 synergistically enhances IL-3-induced activation of the Raf-1/MEK/Erk signalling pathway through activation of Rac and its effector Pak kinases to promote hematopoiesis and chemotaxis. Cell Signal 17: 497–506.
  • Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, Bonadonna RC. (2002). Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 105: 576–82.
  • Avogaro A, de Kreutzenberg SV, Fadini GP. (2008). Oxidative stress and vascular disease in diabetes: is the dicotomization of insulin signalling still valid? Free Radic Biol Med 44:1209–15.
  • Bakker W, Sipkema P, Stehouwer CD, Serne EH, Smulders YM, van Hinsbergh VW, Eringa EC. (2008). Protein kinase C theta activation induces insulin-mediated constriction of muscle resistance arteries. Diabetes 57:706–13.
  • Bar RS, Hoak JC, Peacock ML. (1978). Insulin receptors in human endothelial cells: identification and characterization. J Clin Endocrinol Metab 47:699–702.
  • Baron AD. (1994). Hemodynamic actions of insulin. Am J Physiol 267:E187–202.
  • Baron AD, Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G. (1995). Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 96:786–92.
  • Baron AD, Clark MG. (1997). Role of blood flow in the regulation of muscle glucose uptake. Annu Rev Nutr 17:487–99.
  • Baron AD, Tarshoby M, Hook G, Lazaridis EN, Cronin J, Johnson A, Steinberg HO. (2000). Interaction between insulin sensitivity and muscle perfusion on glucose uptake in human skeletal muscle: evidence for capillary recruitment. Diabetes 49:768–74.
  • Baron AD. (2002). Insulin resistance and vascular function. J Diabetes Complications 16:92–102.
  • Baron GL. (2007). Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance? J Hum Hypertens 21:12–9.
  • Barrett EJ, Eggleston EM, Inyard AC, Wang H, Li G, Chai W, Liu Z. (2009). The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 52:752–64.
  • Bergandi L, Silvagno F, Russo I, Riganti C, Anfossi G, Aldieri E, Ghigo D, Trovati M, Bosia A. (2003). Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23:2215–21.
  • Bhagat K, Vallance P. (1997). Inflammatory cytokines impairs endothelium-dependent dilatation in human veins in vivo. Circulation 96:3042–7.
  • Bobik A, Grooms A, Millar JA, Mitchell A, Grinpukel S. (1990). Growth factor activity of endothelin on vascular smooth muscle. Am J Physiol 258:C408–15.
  • Boden G. (2006). Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep 6:177–81.
  • Bonadonna RC, Saccomani MP, Del Prato S, Bonora E, De Fronzo RA, Cobelli C. (1998). Role of tissue-specific blood flow and tissue recruitment in insulin-mediated glucose uptake of human skeletal muscle. Circulation 98:234–41.
  • Bradley EA, Clark MG, Rattigan S. (2007). Acute effects of wotmannin on insulin’s hemodynamic and metabolic actions in vivo. Am J Physiol Metab 292:E779–87.
  • Cavalot F, Russo I, Mattiello L, Anfossi G, Massucco P, Mularoni E, Hahn AW, Trovati M. (1997). Influence of protamine on adhesion, chemotaxis and proliferation of human vascular smooth muscle cells. Diabetologia 40:67–75.
  • Chou E, Suzuma I, Way KJ, Opland D, Clermond AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, et al. (2002). Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 105:373–9.
  • Clark MG, Wallis MG, Barrett EJ, Vincent MA, Richards SM, Clerk LH, Rattigan S. (2003). Blood flow and muscle metabolism: a focus on insulin action. Am J Physiol Endocrinol Metab 284:E241–58.
  • Clark MG. (2008). Impaired microavascular perfusion: a consequence of vascular dysfuntion and a potential cause of insulin resistance in muscle. Am J Physiol Endocrinol Metab 295: E732–50.
  • Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JM. (1998). Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin Exp Pharmacol Physiol 25:175–84.
  • Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell, JM. (1999). Insulin-mediated vasodilation and glucose uptake are functionally linked in humans. Hypertension 33:554–8.
  • Cleland SJ, Petrie JR, Small M, Elliott HL, Connell JM. (2000). Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension 35:507–11.
  • Clerk LH, Rattigan S, Clark MG. (2002). Lipid infusion impairs physiologic insulin-mediated capillary recruitment and muscle glucose uptake in vivo. Diabetes 51:1138–45.
  • Clerk LH, Vincent MA, Lindner JR, Clark MG, Rattigan S, Barrett EJ. (2004). The vasodilatory actions of insulin on resistance and terminal arterioles and their impact on muscle glucose uptake. Diabetes Metab Res Rev 20:3–12.
  • Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. (2006). Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes 55:1436–42.
  • Cooke JP, Dzau VJ. (1997). Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 48:489–509.
  • Cosentino F, Luscher TF. (1998). Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 32(Suppl 3): S54–S61.
  • Cruzado M, Risler N, Castro C, Ortiz A, Rüttler ME. (1998). Proliferative effect of insulin on cultured smooth muscle cells from rat mesenteric resistance vessels. Am J Hypertens 11: 54–8.
  • Cusi, K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, De Fronzo RA, Kahn CR, Mandarino LJ. (2000). Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signalling in human muscle. J Clin Invest 105: 311–20.
  • Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. (2005). Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes and inflammation. Circulation 111: 1448–54.
  • De Fronzo RA, Ferrannini E. (1991). Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173–94.
  • de Jongh RT, Sernè EH, Ijzerman RG, de Vries G, Stehouwer CD. (2004a). Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy. Diabetes 53: 2873–82.
  • de Jongh RT, Clark AD, Ijzerman RG, Serné; EH, de Vries G, Stehouwer CD. (2004b). Physiological hyperinsulinaemia increases intramuscular microvascular reactive hyperaemia and vasomotion in healthy volunteers. Diabetologia 47: 978–86.
  • de Jongh RT, Sernè; EH, Ijwerman RG, de Vries G, Stehouwer CD. (2004c). Impaired microvascular function in obesity: implications for obesity–associated microangiopathy, hypertension and insulin resistance. Circulation 109: 2529–35.
  • Del Mese P, Russo I, Doronzo G, Mattiello L, Viretto M, Anfossi G, Trovati M.(2007). Oleate induces an insulin resistance “selective” for the PI3-K/Akt pathway in cultured human and rat vascular smooth muscle cells. Diabetologia 50 (Suppl.1): 0239 (abstract).
  • de Luca C, Olefsky JM. (2008). Inflammation and insulin resistance. FEBS Lett 582:97–105.
  • de Winther MP, Kanters E, Kraal G, Hofker MH. (2005). Nuclear factor kappaB signalling in atherogenesis. Arterioscler Thromb Vasc Biol 25:904–14.
  • Dichtl W, Nilsson L, Goncalves I, Ares MP, Banfi C, Calara F, Hamsten A, Eriksson P, Nilsson J. (1999). Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res 84:1085–94.
  • Donatelli M, Colletti I, Bucalo ML, Russo V, Verga S. (1994). Plasma endothelin levels in NIDDM patients with macroangiopathy. Diabetes Res 25:159–64.
  • Donatelli M, Hoffmann E, Colletti I, Andolina G, Russo V, Bucalo ML, Valenti TM, Compagno V, Cataldo MG, Morici ML. (1996). Circulating endothelin-1 levels in type 2 diabetic patients with ischaemic heart disease. Acta Diabetol 33: 246–8.
  • Doronzo G, Russo I, Mattiello L, Anfossi G, Bosia A, Trovati M. (2004). Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance. Eur J Clin Invest 34: 664–73.
  • Doronzo G, Russo I, Mattiello L, Riganti C, Anfossi G, Trovati M. (2006). Insulin activates hypoxia-inducible factor-1alpha in human and rat vascular smooth muscle cells via phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways: impairment in insulin resistance owing to defects in insulin signalling. Diabetologia 49: 1049–63.
  • Doronzo G, Viretto M, Russo I, Del Mese P, Mattiello L, Anfossi G, Trovati M. (2008). Insulin increases matrix metalloproteinase 2 synthesis and secretion and activity in aortic vascular smooth muscle cells though PI3-K pathways: effect reduced by insulin resistance. Diabetologia 51 (Suppl.1): S253 (abstract).
  • Dzau VJ, Braun-Dullaeus RC, Sedding DG. (2002). Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 8: 1249–56.
  • Egan BM, Greene EL, Goodfriend TL. (2001). Nonesterified fatty acids in blood pressure control and cardiovascular complications. Curr Hypertens Rep 3: 107–16.
  • Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, Hotamisligil GS, Van Obberghen E. (2001). SOCS-3 inhibits insulin signalling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 276: 47944–9.
  • Endemann H, Schiffrin EL. (2004). Endothelial dysfunction. J Am Soc Nephrol 15:1983–92.
  • Eringa EC, Stehouwer CD, Merlijn T, Westerhof N, Sipkema P. (2002). Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles. Cardiovasc Res 56: 464–71.
  • Eringa EC, Stehouwer CD, van Nieuw Amerongen GP, Ouwehand L, Westerhof N, Sipkema P. (2004). Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium. Am J Physiol Heart Circ Physiol 287: H2043–8.
  • Eringa EC, Stehouwer CD, Walburg K, Clark AD, van Nieuw Amerongen GP, Westerhof N, Sipkema P. (2006). Physiological concentrations of insulin induce endothelin-dependent vasocontriction of skeletal muscle resistance arteries in the presence to tumor necrosis factor-alpha dependence on c-Jun N.terminal kinase. Arterioscler Thromb Vasc Biol 26: 274–80.
  • Eringa EC, Bakker W, Smulders YM, Sernè EH, Yudkin JS, Stehouwer CD. (2007a). Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue. Microcirculation 14: 389–402.
  • Eringa EC, Stehouwer CD, Roos MH, Westerhof N, Sipkema P. (2007b). Selective resistance to vasoactive effects of insulin in muscle resistance arteries of obese Zucker (fa/fa) rats. Am J Physiol Endocrinol Metab 293: E1134–9.
  • Fadini GP, Pauletto P, Avogaro A, Rattazzi M. (2007). The good and the bad in the link betwen insulin resistance and vascular calcifications. Atherosclerosis 193: 241–4.
  • Ferrannini E, Galvan AQ, Gastaldelli A, Camastra S, Sironi AM, Toschi E, Baldi S, Frascerra S, Monzani F, et al. (1999). Insulin: new roles for an ancient hormone. Eur J Clin Invest 29: 842–52.
  • Ferrannini E, Iozzo P. (2006). Is insulin resistance atherogenic? A review of the evidence. Atheroscler Suppl 7:5–10.
  • Ferrara N, Davis-Smith T. (1997). The biology of vascular endothelial growth factor. Endocrine Rev 18:4–25.
  • Ferri C, Bellini C, Desideri G, Di Francesco L, Baldoncini R, Santucci A, De Mattia G. (1995). Plasma endothelin-1 levels in obese hypertensive and normotensive men. Diabetes 44: 431–6.
  • Ferri C, Bellini C, Desideri G, Baldoncini R, Properzi G, Santucci A, De Mattia G. (1997). Circulating endothelin-1 levels in obese patients with the metabolic syndrome. Exp Clin Endocrinol Diabetes 105(suppl 2):38–40.
  • Filep JG, Sirois MG, Foldes-Filep E, Rousseau A, Plante GE, Fournier A, Yano M, Sirois P. (1993). Enhancement of endothelin-1 of microvascular permeability via the activation of ETA receptors. Br J Pharmacol 109: 880–6.
  • Frisbee JC, Delp MD. (2006). Vascular function in the metabolic syndrome and the effects of skeletal muscle perfusion: lessons from the obese Zucker rat. Essays Biochem 42: 145–61.
  • Frisbee JC. (2007). Vascular dysfunction in obesity and insulin resistance. Microcirculation 14: 269–71.
  • Gaenzer W, Sturm G, Neumayr R, Kirchmair C, Ebenbichler A, Ritsch B, Foger G, Weiss J, Patsch R. (2001). Pronounced postprandial lipemia impairs endothelium-dependent dilation of the brachial artery in men. Cardiovasc Res 52: 509–16.
  • Gerritsen ME. (1996). Physiologic functions of normal endothelial cells. In: Loscalzo J, Creager MA and Dzau J, editors. Vascular medicine: A textbook of vascular biology and diseases. 2nd edn. Boston/New York/Toronto/London: Little Brown and Company Editions, pp. 3–38.
  • Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA. (1991). The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 72:96–107.
  • He Z, Opland DM, Way KJ, Ueki K, Bodayak N, Kang PM, Izumo S, Kulkarni RN, Wang B, Liao R, et al. (2006). Regulation of vascular endothelial growth factor expression and vascularization in the myocardium by insulin receptor and PI3K/Akt pathways in insulin resistance and ischemia. Arterioscler Thromb Vasc Biol 26: 787–93.
  • Hermann C, Assmus B, Urbich C Zeiher AM, Dimmeler S. (2000). Insulin-mediated stimulation of protein kinase Akt: A potent survival signalling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 20: 402–9.
  • Hogikyan RV, Galecki AT, Pitt B, Halter JB, Greene DA, Supiano MA. (1998). Specific impairment of endothelium-dependent vasodilation in subjects with type 2 diabetes independent of obesity. J Clin Endocrinol Metab 83: 1946–52.
  • Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL, Summers SA. (2007). Lipid mediators of insulin resistance. Nutr Rev 65: S39–S46.
  • Hotamisligil GS, Shargill NS, Spiegelman BM. (1993). Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259: 87–91.
  • Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. (1994). Tumor necrosis factor alpha inhibits signalling from the insulin receptor. Proc Natl Acad Sci USA 91: 4854–8.
  • Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. (1995). Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409–15.
  • Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. (1996). IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271: 665–8.
  • Hotamisligil GS. (2003). Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 27 Suppl 3: S53–5.
  • Hsueh WA, Law RE. (1999). Insulin signalling in the arterial wall. Am J Cardiol 84: 21J–4J.
  • Hutley L, Prins JB. (2005). Fat as an endocrine organ: relationship to the metabolic syndrome.Am J Med Sci 330: 280–9.
  • Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Boerwinkle E. (1997). Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary hearts disease cases. The Atherosclerosis Risk in Communities (ARIC) study. Circulation 96: 4219–25.
  • Ijzerman RG, Voordouw JJ, Van Weissenbruch MM, Yudkin JS, Serné EH, Delemarre-van de Waal HA, Stehouwer CD. (2006). TNF-alpha levels are associated with skin capillary recruitment in humans: a potential explanation for the relationship between TNF-alpha and insulin resistance. Clin Sci 110: 361–8.
  • Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, et al. (2000). High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49: 1939–45.
  • Irving RJ, Noon JP, Watt GC, Webb DJ, Walker BR. (2001). Activation of the endothelin system in insulin resistance.QJM 94: 321–6.
  • Ishibashi KI, Imamura T, Sharma PM, Huang J, Ugi S, Olefsky JM. (2001). Chronic endothelin-1 treatment leads to heterologous desensitization of insulin signalling in 3T3-L1 adipocytes. J Clin Invest 107:1193–202.
  • Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL. (1999a). Characterization of selective resistance to insulin signalling in the vasculature of obese Zuker (fa/fa) rats. J Clin Invest 104:447–57.
  • Jiang ZY, Zhou QL, Chatterjee A, Feener EP, Myers MG, White MF, King GL. (1999b). Endothelin-1 modulates insulin signalling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. Diabetes 48: 1120–30.
  • Jiang ZY, He Z, King BL, Kuoroki T, Opland DM, Suzuma K, Suzuma I, Ueki K, Kulkarni RN, Kahn CR, King GL. (2003). Characterization of multiple signalling pathways in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. J Biol Chem 278: 31964–71.
  • Johansson GS, Arnqvist HJ. (2006). Insulin and IGF-I action on insulin receptors, IGF-I receptors, and hybrid insulin/IGF-I receptors in vascular smooth muscle cells. Am J Physiol Endocrinol Metab 291: E1124–30.
  • Jonas M, Edelman ER, Groothuis A, BakerAB, Seifert P, Rogers C. (2005). Vascular neointimal formation and signalling pathway activation in response to stent injury in insulin–resistant and diabetic animals. Circ Res 97: 725–33.
  • Juan CC, Fang VS, Huang YJ, Kwok CF, Hsu YP, Ho LT. (1996). Endothelin-1 induces insulin resistance in conscious rats. Biochem Biophys Res Commun 227: 694–9.
  • Kahn AM, Husid A, Allen JC, Seidel CL, Song T. (1997). Insulin acutely inhibits cultured vascular smooth muscle cell contraction by a nitric oxide synthase-dependent pathway. Hypertension 30: 928–33.
  • Kim J, Montagnani M, Koh KK, Quon MJ. (2006). Reciprocal relationships between insulin resistance and endothelial dysfunction, molecular and pathopysiological mechanisms. Circulation 113: 1888–904.
  • King GL, Buzney SM, Kahn CR, Hetu N, Buchwald S, Macdonald SG, Rand LI. (1983). Differential responsiveness to insulin of endothelial and support cells from micro and macrovessels. J Clin Invest 71: 974–9.
  • Kornowski R, Mintz GS, Kent KM, Pichard AD, Satler LF, Bucher TA, Hong MK, Popma JJ, Leon MB. (1997). Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: a serial intravascular ultrasound study. Circulation 95: 1366–9.
  • Kuboki K, Liang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL. (2000). Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 101: 670–81.
  • Kubota T, Kubota N, Moroi M, Terauchi Y, Kobayashi T, Kamata K, Suzuki R Tobe K, Namiki A, Aizawa S, et al. (2003). Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation 107: 3073–80.
  • Kuhlmann J, Neumann-Haefelin C, Belz U, Kalisch J, Juretschke HP, Stein M, Kleinschmidt E, Kramer W, Herling AW. (2003). Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats. Diabetes 52:138–44.
  • Laakso M, Edelman SV, Brechtel G, Baron AD. (1990). Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 85:1844–52.
  • Laight DW, Kengatharan KM, Gopaul NK, Anggard EE, Carrier MJ. (1998). Investigation of oxidant stress and vasodepression to glyceryl trinitrate in the obese Zucker rat in vivo. Br J Pharmacol 125:895–901.
  • Laine H, Yki-Jarvinen H, Kirvela O, Tolvanen T, Raitakari M, Solin O, Haaparanta M, Knuuti J, Nuutila P. (1998). Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity. J Clin Invest 101:1156–62.
  • Lavrencic A, Salobir BG, Keber I. (2000). Physical training improves flow-mediated dilation in patients with the polymetabolic syndrome. Arterioscler Thromb Vasc Biol 20:551–5.
  • Lee JH, Ragolia L. (2006). AKT phosphorylation is essential for insulin–induced relaxation of rat vascular smooth muscle cells. Am J Physiol Cell Physiol 291:C1355–65.
  • Lee YC, Juan CC Fang VS, Hsu YP, Lin SH, Kwok CF, Ho LT. (1998). Evidence that endothelin-1 (ET-1) inhibits insulin-stimulated glucose uptake in rat adipocytes mainly through ETA receptors. Metabolism 47:1468–71.
  • Leyva F, Wingrove C, Felton C, Stevenson JC. (1997). Physiological hyperinsulinemia is not associated with alterations in venous plasma levels of endothelin-1 in healthy individuals. Metabolism 56:1137–9.
  • Li Y, Soos TJ, Li X, Wu J, Degennaro M, Sun X, Littman DR, Birnbaum, MJ, Polakiewicz, RD. (2004). Protein kinase C Theta inhibits insulin signalling by phosphorylating IRS1 at Ser (1101). J Biol Chem 279:45304–7.
  • Liu S. Premont RT, Kontos CD, Huang J, Rockey DC. (2003). Endothelin-1 activates endothelial cell nitric–oxide synthase via heterotrimeric G-protein betagamma subunit signalling to protein kinase B/Akt. J Biol Chem 278:49929–35.
  • Lteif A, Vaishanava P, Baron AD, Mather J. (2007). Endothelin limits insulin action in obese/insulin–resistant humans. Diabetes 56:728–34.
  • Lteif AA, Fulford AD, Considine RV, Gelfand I, Baron AD, Mather KJ. (2008). Hyperinsulinemia fails to augment ET-1 action in skeletal muscle vascular bed in vivo in humans. Am J Physiol Endocrinol Metab 295:E1510–7.
  • Madonna R, Pandolfi A, Massaro M, Consoli A, De Caterina R. (2004). Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein kinase. Diabetologia 47:532–6.
  • Madonna R, Massaro M, Pandolfi A, Consoli A, De Caterina R. (2007). The prominent role of p38 mitogen-activated protein kinase in insulin-mediated enhancement of VCAM-1 expression in endothelial cells. Int J Immunopathol 20:539–55.
  • Madonna R, Massaro M, De Caterina R. (2008). Insulin potentiates cytokine-induced VCAM-1 expression in human endothelial cells. Biochim Biophys Acta 1782:511–6.
  • Madonna R, De Caterina R. (2009). Prolonged exposure to high insulin impairs the endothelial PI3 kinase/Akt/nitric oxide signalling. Thromb Haemost 101:345–50.
  • Maeda S, Jesmin S, Iemitsu M, Otsuki T, Matsuo T, Ohkawara K, Nakata Y, Tanaka K, Goto K, Miyauchi T. (2006). Weight loss reduces plasma endothelin-1 concentration in obese men. Exp Biol Med 231:1044–7.
  • Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, Lennon L, Thomson A, Haskard D. (2001). Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358:971–6.
  • Marasciulo FL, Montagnani M, Potenza MA. (2006). Endothelin-1: the yin and yang on vascular function. Curr Med Chem 13:1655–65.
  • Martens FM; Rabelink TJ, op ‘,t Roodt J, de Koning EJ, Visseren, FL. (2006). TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J 27:1605–9.
  • Masaki T. (1998). The discovery of endothelins. Cardiovasc Res 39:530–3.
  • Mather K, Laakso, M, Edelman, S, Hook G, Baron A. (2000). Evidence for physiological coupling of insulin–mediated glucose metabolism and limb blood flow. Am J Physiol Endocrinol Metab 279:E1264–70.
  • Mather KJ, Verma S, Anderson TJ. (2001). Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 37:1344–50.
  • Mather K, Mirzamohammadi B, Lteif A, Steinberg H, Baron A. (2002). Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes mellitus. Diabetes 51:3517–23.
  • Mather KJ, Lteif A, Steinberg HO Baron AD. (2004). Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 53:2060–6.
  • McMillen MA, Huribal M, Cunningham ME, Kumar R, Sumpio BE. (1995). Endothelin-1 increases intracellular calcium in human monocytes and causes production of interleukin-6. Crit Care Med 23:34–40.
  • McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR. (1992). Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:771–6.
  • Metsarinne K, Saijonmaa O, Yki-Järvinen H, Fyhrquist F. (1994). Insulin increases the release of endothelin in endothelial cell cultures in vitro but not in vivo. Metabolism 43:878–82.
  • Miyazaki Y, Pipek R, Mandarino LJ, DeFronzo RA. (2003). Tumor necrosis factor alpha and insulin resistance in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 27:88–94.
  • Moncada S, Higgs EA. (2006). Nitric oxide and the vascular endothelium. Handb Exp Pharmacol 176(Pt 1):213–54.
  • Montagnani M, Golovchenko I, Kim I, Koh, GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ, Draznin B. (2002). Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 277:1794–9.
  • Mooney RA, Senn J, Cameron S, Inamdar N, Boivin LM, Shang Y, Furlanetto RW. (2001). Suppressors of cytokine signalling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 276:25889–93.
  • Muniyappa R, Montagnani M, Koh KK, Quon MJ. (2007a). Cardiovascular actions of insulin. Endocr Rev 28:463–91.
  • Muniyappa R, Quon MJ. (2007b). Insulin action and insulin resistance in vascular endothelium. Curr Opin Clin Nutr Metab Care 10:523–30.
  • Murad F. (2006). Nitric oxide and cyclic GMP in cell signalling and drug development. N Engl J Med 355:2003–11.
  • Natali A, Bonadonna R, Santoro D, Galvan AQ, Baldi S, Frascerra S, Palombo C, Ghione S, Ferrannini E. (1994). Insulin resistance and vasodilation in essential hypertension. Studies with adenosine. J Clin Invest 94:1570–6.
  • Natali A, Quinones Galvan A, Pecori N, Sanna G, Toschi E, Ferrannini E. (1998). Vasodilation with sodium nitroprusside does not improve insulin action in essential hypertension. Hypertension 31:632–6.
  • Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. (2008). Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem 114:183–94.
  • Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. (1998). Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 18:1199–202.
  • Olefsky J, Farquhar JW, Reaven G. (1973). Relationship between fasting plasma insulin level and resistance to insulin–mediated glucose uptake in normal and diabetic subjects. Diabetes 22:507–13.
  • Oliver FJ, de la Rubia G, Feener EP, Lee ME, Loeken MR, Shiba T, Quertermous T, King GL. (1991). Stimulation of endothelin-1 gene by insulin in endothelial cells. J Biol Chem 266:23251–6.
  • Ottosson-Seeberger A, Lundberg, JM, Alvestrand A, Ahlborg G. (1997). Exogenous endothelin-1 causes peripheral insulin resistance in healthy humans. Acta Physiol Scand 161:211–20.
  • Pacher P, Beckman JS, Liaudet L. (2007). Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315–424
  • Pandolfi A, Iacoviello I, Capani F, Vitacolonna E, Donati MB, Consoli A. (1996). Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle in culture. Diabetologia 39:1425–31.
  • Patel JN, Jager A, Schalkwijk C, Corder R, Douthwaite JA, Yudkin JS, Coppack SW, Stehouwer CD. (2002). Effects of tumour necrosis factor-alpha in the human forearm: blood flow and endothelin-1 release. Clin Sci 103:409–15.
  • Perticone F, Sciacqua A, Scozzafava A, Ventura G, Laratta E, Pujia A, Federici M, Lauro R. Sesti G. (2004). Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. J Clin Endocrinol Metab 89:3606–9.
  • Pessin JE, Saltiel AR. (2000). Signalling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106:165–9.
  • Peuler JD, Phare SM, Iannucci AR, Hodorek MJ. (1996). Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. Am J Hypertens 9:188–92.
  • Piatti PM, Monti LD, Conti M, Baruffaldi L, Galli L, Phan CV, Guazzini B, Pontiroli AE, Pozza, G. (1996). Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 45:316–21.
  • Piatti P, Di Mario C, Monti LD, Fragasso D, Sgura F, Caumo A, Setola E, Lucotti P, Galluccio E, Ronchi C et al. (2004). Association of insulin resistance, hyperleptinemia and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 108:2074–81.
  • Pugh CW, Ratcliffe PJ. (2003). Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9:677–84.
  • Rask-Madsen C, Dominguez H, Ihlemann N, Hermann T, Kober L, Torp-Pedersen C. (2003). Tumor necrosis factor-alpha inhibits insulin’s stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 108:1815–21.
  • Rattigan S, Bussey CT, Ross RM, Richards SM. (2007). Obesity, insulin resistance, and capillary recruitment. Microcirculation 14:299–309.
  • Reaven GM. (2003). Insulin resistance/compensatory hyperinsulinemia, essential hypertension and cardiovascular disease. Clin Endocrinol Metab 88:2399–403.
  • Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. (1998). Plasma concentration of soluble intracellular adhesion molecule-1 and risk of future myocardial infarction in apparently healthy men. Lancet 351:88–92.
  • Ross R. (1993). The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:801–9.
  • Ross RM, Kolka CM, Rattigan S, Clark MG. (2007). Acute blockade by endothelin-1 on haemodynamic insulin action in rats. Diabetologia 50:443–51.
  • Rui L, Yuan M, Frantz D, Shoelson S, White MF. (2002). SOCS-1 and SOCS-3 block insulin signalling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277:42394–8.
  • Russo I, Del Mese P, Doronzo G, Mattiello L, Viretto M, Bosia A, Anfossi G, Trovati M. (2008). Resistance to the nitric oxide/cyclic guanosine 5’-monophosphate/protein kinase G pathway in vascular smooth muscle cells from the obese zucker rat, a classical animal model of insulin resistance: role of oxidative stress. Endocrinology 149:1480–9.
  • Sainsbury CA, Satter N, Connell JM, Hillier C, Petrie JR. (2004). Non-esterified fatty acids impair endothelium-dependent vasodilation in rat mesenteric resistance vessels. Clin Sci 107: 625–9.
  • Sarafidis PA, Bakris GL. (2007). Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance? J Hum Hypertens 21:12–9.
  • Sasaoka T, Rose DW, Jhun BH, Saltiel AR, Draznin B, Olefsky JM. (1994). Evidence for a functional role of Shc proteins in mitogenic signalling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. J Biol Chem 269:13689–94.
  • Sasaoka T, Ishiki M, Sawa T, Ishihara H, Takata Y, Imamura T, Usui I, Olefsky JM, Kobayashi M. (1996). Comparison of the insulin and insulin-like growth factor 1 mitogenic intracellular signalling pathways. Endocrinology 137:4427–34.
  • Schalkwijk CG, Stehouwer CD. (2005). Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci 109:143–59.
  • Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. (1994). Nitric oxide release accounts for insulin’s vascular effects in humans. J Clin Invest 94:2511–5.
  • Serné; EH, Ijzerman RG, Gans RO, Nijveldt R, de Vries G, Evertz R, Donker AJ, Stehouwer CD. (2002). Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia. Diabetes 51:1515–22
  • Shulman GI. (1999). Cellular mechanisms of insulin resistance in humans. Am J Cardiol 84:3J–10J.
  • Sjöstrand M, Gudbjörnsdottir S, Holmäng A, Lönn L, Strindberg L, Lönnroth P. (2002). Delayed transcapillary transport of insulin to muscle interstitial fluid in obese subjects. Diabetes 51:2742–8.
  • Stamler JS, Dzau VJ. Loscalzo J. (1996). The vascular smooth muscle cell. In: Loscalzo J, Creager MA and Dzau J, editors. Vascular medicine: A textbook of vascular biology and diseases. 2nd edn. Boston/New York/Toronto/London: Little Brown and Company Editions, pp. 69–116
  • Stankova J, Rola-Pleszczynski M, D’Orleans-Juste P. (1995). Endothelin 1 and thrombin synergistically stimulate IL-6 mRNA expression and protein production in human umbilical vein endothelial cells. J Cardiovasc Pharmacol 26 (Suppl 3):S505–7.
  • Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. (1994). Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 94:1172–9.
  • Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. (1996). Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97:2601–10.
  • Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed N, Baron AD. (1997). Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100:1230–9.
  • Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. (2000). Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 49:1231–8.
  • Steinberg HO, Baron, AD. (2002). Vascular function, insulin resistance and fatty acids. Diabetologia 45:623–34.
  • Strawbridge AB, Elmendorf JS. (2005). Phosphatidylinositol 4,5-bisphosphate reverses endothelin-1-induced insulin resistance via an actin-dependent mechanism. Diabetes 54:1698–705.
  • Sung BH, Izzo JL, Dandona P, Wilson MF. (1999). Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 34:83–8.
  • Suzuki LA, Poot M, Gerrity RG, Bornfeldt KE. (2001). Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. Diabetes 50:851–60.
  • Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, Yoshida K. (2002). Impact of insulin resistance on neointimal tissue proliferation after coronary stent implantation: Intravascular ultrasound studies. J Diabetes Complications 16:50–5.
  • Takahashi K, Ghatei MA, Lam HC, O’Halloran DJ, Bloom SR. (1990). Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 33:306–10.
  • Takahashi S, Mendelsohn ME. (2003). Synergistic activation of endothelial nitric-oxide synthase (eNOS) by HSP90 and Akt: calcium-independent eNOS activation involves formation of an HSP90-Akt-CaM-bound eNOS complex. J Biol Chem 278:30821–7.
  • Taniguchi CM, Emanuelli B, Kahn CR. (2006). Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7:85–96.
  • Tesauro M, Schinzari F, Rovella V, Melina D, Mores N, Barini A, Mettimano M, Lauro D, Iantorno M, Quon MJ, et al. (2008). Tumor necrosis factor-alpha antagonism improves vasodilation during hyperinsulinemia in metabolic syndrome. Diabetes Care 31:1439–41.
  • Trovati M, Massucco P, Mattiello L, Cavalot F, Mularoni E, Hahn A, Anfossi G. (1995). Insulin increases cyclic nucleotide content in human vascular smooth muscle cells: a mechanism potentially involved in insulin-induced modulation of vascular tone. Diabetologia 38: 936–41.
  • Trovati M, Massucco P, Mattiello L, Cavalot F, Mularoni EM, Hahn AW; Anfossi G. 1996. Studies on the influence of insulin on cyclic adenosine monophosphate in human vascular smooth muscle cells: dependence on cyclic guanosine monophosphate and modulation of catecholamine effects. Diabetologia 1996 39:1156–64.
  • Trovati M, Anfossi G. (1998). Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured vascular smooth muscle cells. Diabetologia 41:609–22.
  • Trovati M, Massucco P, Mattiello L, Costamagna C, Aldieri E, Cavalot F, Anfossi G, Bosia A, Ghigo D. (1999). Human vascular smooth muscle cells express a constitutive nitric oxide synthase that insulin rapidly activates, thus increasing guanosine 3´:5´-cyclic monophosphate and adenosine 3´:5´-cyclic monophosphate concentrations. Diabetologia 42:831–9.
  • Trovati M, Anfossi G. (2002). Influence of insulin and of the insulin resistance on platelets and vascular smooth muscle cell function. J Diabetes Complications 16:35–40.
  • Tsai EJ, Kass DA. (2009). Cyclic GMP signalling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 122:216–38.
  • Ueki K, Kondo T, Kahn CR. (2004). Suppressor of cytokine signalling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434–46.
  • Verma S, Yao L, Dumont A, McNeill J. (2000). Metformin treatment corrects vascular insulin resistance in hypertension. J Hypertens 18:1445–50.
  • Verma S, Anderson TJ. (2002). Fundamentals of endothelial function for the clinical cardiologist. Circulation 105: 546–9.
  • Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H. (2000). Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 20: 545–50
  • Vincent MA, Dawson D, Clark AD, Lindner JR, Rattigan S, Clark MG, Barrett EJ. (2002). Skeletal muscle microvascular recruitment by physiological hyperinsulinemia precedes increases in total blood flow. Diabetes 51:42–8.
  • Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. (2003a). Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab 285:E123–9.
  • Vincent D, Ilany J, Kondo T, Naruse K, Fisher SJ, Kisanuki YY, Bursell S, Yanagisawa M, King GL, Kahn CR. (2003b). The role of endothelial insulin signalling in the regulation of vascular tone and insulin resistance. J Clin Invest 111:1373–80.
  • Vincent MA, Clerk LH, Lindner JR, Klibanov AL, Clark MG, Rattigan S, Barrett EJ. (2004). Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 53:1418–23.
  • Vita JA, Keaney JF, Loscalzo J. (1996). Endothelial dysfunction in vascular disease. In: Loscalzo J, Creager MA and Dzau J, editors. Vascular medicine: A textbook of vascular biology and diseases. 2nd edn. Boston/New York/Toronto/London: Little Brown and Company Editions, pp. 245–63.
  • Wallis MG, Wheatley CM, Rattigan S, Barrett EJ, Clark AD, Clark MG. (2002). Insulin mediated hemodynamic changes are impaired in muscle of Zucker obese rats. Diabetes 51:3492–8.
  • Wang CC, Gurevich I, Draznin B. (2003). Insulin affects vascular smooth muscle cell phenotype and migration via distinct signalling pathways. Diabetes 52:2562–9.
  • Wang, CC, Goalstone ML, Draznin B. (2004). Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 53:2735–40.
  • Wang XL, Zhang L, Youker K, Zhang MX, Wang J, LeMaire SA, Coselli JS, Shen YH. (2006). Free fatty acids inhibit insulin signalling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase. Diabetes 55:2301–10.
  • Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, Yki-Jarvinen H. (1999).Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity. Diabetes 48: 821–7.
  • Westerbacka J, Seppala-Lindroos A, Yki-Jarvinen H. (2001a). Resistance to acute insulin induced decreases in large artery stiffness accompanies the insulin resistance syndrome. J Clin Endocrinol Metab 86: 5262–8.
  • Westerbacka J, Yki-Jarvinen H. (2001b). Arterial stiffness and insulin resistance. Semin Vasc Med 2:157–64.
  • Wiernsperger N, Nivoit P, De Aguiar LG, Bouskela E. (2007). Microcirculation and the metabolic syndrome. Microcirculation 14: 403–38.
  • Wilkes JJ, Hevener A, Olefsky J. (2003). Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes 52: 1904–9.
  • Xi XP, Graf K, Goetze S, Hsueh WA, Law RE. (1997). Inhibition of MAP kinase blocks insulin-mediated DNA synthesis and transcriptional activation of c-fos by Elk-1 in vascular smooth muscle cells. FEBS Lett 417: 283–6.
  • Yenush L, Zanella C, Uchida T, Bernal D, White MF. (1998). The pleckstrin homology and phosphotyrosine binding domains of insulin receptor substrate 1 mediate inhibition of apoptosis by insulin. Mol Cell Biol 18: 6784–94.
  • Yilmaz MB, Biyikoglu SF, Akin Y, Guray U, Kisacik HL, Korkmaz S. (2003). Obesity is associated with impaired coronary vessel development. Int J Obes Relat Metab Disord 27: 1541–5.
  • Yki-Järvinen H, Utriainen T. (1998). Insulin-induced vasodilatation: physiology or pharmacology? Diabetologia 41:369–79.
  • Yki-Jarvinen H, Westerbacka J. (2000). Vascular actions of insulin in obesity. Int J Obes Relat Metab Disord 24 (Suppl. 2): S25–8.
  • Yki-Jarvinen H. (2003). Insulin resistance and endothelial dysfunction. Best Pract Res Clin Endocrinol Metab 17:411–30.
  • Youngren JF. (2007). Regulation of insulin receptor function. Cell Mol Life Sci 64b: 873–91.
  • Yoshimura A, Naka T, Kubo M. (2007). SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7: 454–65.
  • Youd JM, Rattigan S, Clark MG. (2000). Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF-α. Diabetes 49:1904–9.
  • Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. (1999). C–reactive protein in healthy subjects: associations with obesity, insulin–resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19: 972–8.
  • Yudkin JS, Eringa E, Stehouwer CD. (2005). “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 365: 1817–20.
  • Yuen DY, Dwyer RM, Matthews VB, Zhang L, Drew BG, Neill B, Kingwell BA, Clark MG, Rattingan S, Febbraio MA. (2009). Interleukin-6 attenuates insulin-mediated increases in endothelial cell signalling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor-alpha expression. Diabetes 58:1086–95.
  • Zemel MB, Reddy S, Sowers JR. (1991). Insulin attenuation of vasoconstrictor responses to phenylephrine in Zucker lean and obese rats. Am J Hypertens 4:537–9.
  • Zeng G, Quon MJ. (1996). Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 98:894–8.
  • Zhang L, Vincent MA, Richards SM, Clerk LH, Rattigan S, Clark MG. Barrett EJ. (2004). Insulin sensitivity of muscle capillary recruitment in vivo. Diabetes 53:447–53.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.